Thomas Cash
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Background The single‐agent pediatric maximum tolerated dose (MTD) of nab‐paclitaxel is significantly higher than adult dosing. We conducted a Phase I trial to establish the MTD/recommended Phase 2 dose (RP2D) of nab‐paclitaxel with gemcitabine in children with relapsed/refractory solid tumors. Methods Nab‐paclitaxel was administered intravenously with fixed‐dose gemcitabine on days 1, 8, and 15 of 28‐day cycles. Three dose levels (DL) of nab‐paclitaxel, 180, 210, and 240 mg/m 2 , were evaluated using a rolling six design. Toxicity, nab‐paclitaxel pharmacokinetics (PK), and radiologic responses were evaluated. Pretreatment tumor tissue was assessed for SPARC and CAV‐1. Results Twenty‐four patients enrolled, 22 received therapy, and 20 were evaluable for dose‐limiting toxicity (DLT): 17 during dose escalation and 3 in dose expansion at the MTD. Median age was 12.5 years. Diagnoses included osteosarcoma ( n = 11), neuroblastoma ( n = 4), and rhabdomyosarcoma ( n = 4). At the starting dose level (gemcitabine 1000 mg/m 2 , nab‐paclitaxel 180 mg/m 2 ), two of five patients experienced DLT, prompting an amendment lowering gemcitabine to 675 mg/m 2 /dose. Post‐amendment, nab‐paclitaxel 240 mg/m 2 /dose with gemcitabine 675 mg/m 2 /dose was identified as the MTD. Grade ≥3 hematologic toxicities were common. Two patients experienced a partial response (Wilms tumor and osteosarcoma), and PK exhibited linearity across DL. SPARC immunoreactivity was present in most tumors, while CAV‐1 immunoreactivity was infrequent. Conclusions The MTD/RP2D of nab‐paclitaxel with gemcitabine in patients with relapsed/refractory pediatric solid tumors is nab‐paclitaxel 240 mg/m 2 /dose and gemcitabine 675 mg/m 2 /dose on days 1, 8, and 15 of 28‐day cycles; responses were limited in this patient population.
Year:
2025
PURPOSE We conducted a phase I trial to determine the safety, tolerability, and preliminary antitumor activity of 131 I-metaiodobenzylguanidine (MIBG) combined with the anti-GD2 antibody dinutuximab with or without the histone deacetylase inhibitor vorinostat in patients with relapsed/refractory neuroblastoma (rNBL). METHODS In part A, patients with MIBG-avid rNBL received MIBG intravenously (IV) on day 1 at 12, 15, or 18 mCi/kg per the rolling six design and dinutuximab (17.5 mg/m 2 once daily) IV on days 8-11 and 29-32 and granulocyte-macrophage colony-stimulating factor (250 mcg/m 2 once daily) subcutaneously on days 8-17 and 29-38. Autologous stem cells were infused on day 15. In part B, vorinostat at 180 mg/m 2 once daily was given orally on days 0-13 in combination with the part A recommended phase II dose (RP2D). Patients could receive two courses. RESULTS Forty-five eligible patients enrolled, of whom 31 were evaluable. The median age was 7.5 (range, 2.9-24.1) years. For part A (n = 19), no dose-limiting toxicities (DLTs) occurred across all dose levels and courses, establishing the RP2D of MIBG to be 18 mCi/kg. In part B (n = 12), 1 DLT (grade 3 hypokalemia) occurred during course 1, and 3 of 11 patients who received a second course experienced DLT: grade 3 ALT increase, grade 4 hypoxia and grade 5 pneumonitis, and grade 3 fatigue. The best overall response rate (BORR; complete response [CR] + partial response [PR]) on part A was 42% with a CR/PR/minor response (MR) rate of 46%, and 19% progressive disease (PD) rate. For part B, the BORR was 42% with a CR/PR/MR rate of 75% and 0% PD rate. CONCLUSION MIBG combined with dinutuximab was well tolerated with encouraging antitumor activity. Vorinostat added to this combination may augment responses in this heavily pretreated patient population.
Year:
2025
Introduction The COVID‐19 pandemic onset had a global debilitating impact on individuals and on burgeoning careers. In 2021, the Children's Oncology Group Young Investigators Committee, Young SIOP (International Society of Paediatric Oncology) Network, and Young SIOPE (European Society for Paediatric Oncology) co‐sponsored a survey to explore the impacts of the first year of the pandemic on early‐career pediatric oncology professionals with respect to working practices, productivity, professional and career development, personal wellbeing, and changing childcare needs. Methods The survey comprised demographic, multiple‐choice, and free‐text questions, and was distributed via email and social media with English, French, and Spanish versions available. Descriptive statistics and chi‐square tests were used to compare quantitative data by self‐designated gender and country of origin. Qualitative data were described using content analysis. Results Professionals ( N = 499, 26.3% male, 77.2% MDs) in 48 countries (77.6% high income) responded in English (79.4%), Spanish (12.4%), and French (8.2%). Respondents had difficulty obtaining and keeping jobs (26.9%), worsened overall academic productivity (50.7%, with higher rates among bench scientists, p < 0.01), and decreased career opportunities (40.9%). Childcare challenges impacted 56.7% of respondents and was felt more negatively among women ( p = 0.008) and in high‐income settings ( p < 0.0001). Qualitative data ( n = 300) highlighted these differences were often attributable to diminished professional/personal boundaries and impacted their personal wellbeing. Conclusion The COVID‐19 pandemic significantly impacted early‐career academic and clinical professionals working in pediatric oncology, with unique challenges noted among those with childcare responsibilities. Career disruptions that resulted from the pandemic should be considered and mitigated by governing bodies and hiring institutions.
Year:
2024
Year:
2022
Collaborators (12)
Daniel Benedetti
Vanderbilt University Medical Center
Amy Erbe
Research Assistant Professor
University of Wisconsin-Madison
Yael Mosse
Professor
University of Pennsylvania
Paul Sondel
Professor
University of Wisconsin-Madison
Kelly C. Goldsmith
Professor
Emory University
Navin Pinto
Professor of Pediatrics
Children's Hospital Colorado
Shahab Asgharzadeh
University of Southern California
Brian Weiss
Division Chief
Riley Hospital for Children at Indiana University Health
Katherine Matthay
Professor
University of California, San Francisco
Julie Park
Chair
St. Jude Children's Research Hospital
Janice Withycombe
Associate Professor
Clemson University
Jennifer Zaborek
University of Wisconsin-Madison
Make your next move.
Prepare your application
Review drafts before you send them.